Transarterial Chemoembolization

Phase 2Small molecule

Transarterial Chemoembolization is one of 31 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Sovaldi

Gilead

Preclinical

1 2

Ibrance

Pfizer

Preclinical

1 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Transarterial Chemoembolization

ZZhejiang University

Phase 2

2 5

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 6

Doptelet

AAkarx

Preclinical

1 7

Opdivo

Bristol-Myers Squibb

Preclinical

2 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

QL1706

Qilu Pharmaceutical Co., Ltd.

Preclinical

5 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Stereotactic Body Radiation Therapy (SBRT)

NCT03895359

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

Completed·PPolaris Group·Phase 2·NCT02006030·30 enrolled

Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma

Unknown status·SSherief Abd-Elsalam·Phase 3·NCT02646137·50 enrolled

Gastric Cancer1 trial

Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC)

Unknown status·GGang Wu·Phase 2·NCT05361161·60 enrolled

Combination Therapy1 trial

Survival Analysis: TACE vs. Combination Therapy in HCC

Completed·ZZhejiang University··NCT06261138·279 enrolled

Stereotactic Body Radiation Therapy (SBRT)1 trial

Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma

Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 3·NCT03895359·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Transarterial Chemoembolization. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Transarterial Chemoembolization compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Transarterial Chemoembolization. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: ZZhejiang University

Transarterial Chemoembolization

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Gastric Cancer1 trial

Combination Therapy1 trial

Stereotactic Body Radiation Therapy (SBRT)1 trial

References

Drug Info

Quick Facts

Related News